KTTA•benzinga•June 2, 2025 at 12:14 PM

Pasithea Announces Its PAS-004 Shows Early Activity And Durable Disease Stability In Heavily Pretreated Solid Tumors, Including BRAF-Mutated Melanoma, With Favorable Safety And Pharmacokinetics In Ongoing Phase 1 Dose Escalation Trial

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 2, 2025 by benzinga